Table 1 Association of DCD expression and Breast Cancer Biomarkers
From: Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling
A. Association between the clinical-pathological features and molecular markers in DCD-positive breast cancer patient samples | |||
|---|---|---|---|
Characteristics | Invasive Breast Carcinoma, n = 26 | ||
Median age, years range | 56 (37–79) |  | |
DCD expression | <50% | >50% | Â |
| Â | no. (%) | no. (%) | P-value |
Nodal status | Â | Â | Â |
Negative, n = 9 | 7 (77.8) | 2 (22.2) | 0,11 |
Positive, n = 17 | 7 (41.1) | 10 (58.9) |  |
Histological Grade | Â | Â | Â |
Intermediate, n = 10 | 7 (70) | 3 (30) | 0,008 |
High, n = 16 | 2 (12.5) | 14 (87.5) |  |
Estrogen Receptor | Â | Â | Â |
Negative, n = 15 | 6 (40) | 9 (60) | 0,13 |
Positive, n = 11 | 8 (72.7) | 3 (27.3) |  |
Progesterone Receptor | Â | Â | Â |
Negative, n = 16 | 6 (37.5) | 10 (62.5) | 0,22 |
Positive, n = 10 | 7 (70) | 3 (30) |  |
ERBB2 | Â | Â | Â |
Score 0–2, n = 14 | 14 (100) | 0 | 0,001 |
Score 3, n = 12 | 0 | 12 (100) |  |
B. Association between DCD and ERBBs mRNA expression in 55 breast cancer cell lines | |||
| Â | DCD expression (RMA,log2) | Â | |
|  | <4 | ≥4 |  |
| Â | no. (%) | no. (%) | P-value |
ERBB2 | Â | Â | Â |
<8, n = 25 | 13 (23.6) | 12 (21.8) | 0,047 |
≥8, n = 30 | 7 (12.7) | 23 (41.8) |  |
ERBB3 | Â | Â | Â |
<9, n = 21 | 12 (21.8) | 9 (16.3) | 0,044 |
≥9, n = 34 | 9 (16.3) | 25 (45.4) |  |
ERBB4 | Â | Â | Â |
<4, n = 21 | 10 (18.1) | 11 (20) | 0,391 |
≥4, n = 34 | 11 f | 23 (41.8) |  |
EGFR | Â | Â | Â |
<7, n = 40 | 17 (30.9) | 23 (41.8) | 0,795 |
≥7, n = 15 | 5 (0.05) | 10 (14.5) |  |